Immunovant Sciences GmbH

Address: Viaduktstrasse 8

Sponsor Overview

assignment

Specializations

Autoimmune thyroid disease and thyroid eye disease

Immunovant Sciences GmbH funds clinical research in Graves’ disease, thyroid eye disease, and related thyroid hormone dysregulation, with attention to endocrine and orbital manifestations.

Graves’ disease
Thyroid eye disease
Proptosis
Thyroid-stimulating hormone and free thyroid hormones

Its research activity also extends to maintaining euthyroidism and evaluating outcomes tied to antithyroid therapy.

Neuromuscular autoimmune disorders

The sponsor is active in studies of generalized myasthenia gravis, including antibody-positive disease, with a focus on muscle weakness and daily function.

Generalized myasthenia gravis
AChR antibody-positive disease
MG-ADL functional outcomes
Induction and maintenance therapy

These trials reflect interest in clinical measures of strength, activity limitation, and longer-term disease control.

Peripheral nerve inflammation and immune-mediated neuropathy

Immunovant Sciences GmbH supports research in chronic inflammatory demyelinating polyneuropathy, addressing relapse prevention, neurological function, and treatment durability.

Chronic inflammatory demyelinating polyneuropathy (CIDP)
Adjusted INCAT neurological assessment
Relapse prevention
Long-term safety and tolerability

Some studies include participants receiving immunoglobulin therapy or plasma exchange, indicating interest in treatment settings used in active neuropathic disease.

Systemic rheumatologic and connective tissue disease

The sponsor funds trials in rheumatoid arthritis, primary Sjögren’s disease, and cutaneous lupus erythematosus, spanning inflammatory joint, glandular, and skin involvement.

ACPA-positive rheumatoid arthritis
Primary Sjögren’s disease
Cutaneous lupus erythematosus
Systemic disease activity and skin disease scores

Clinical outcomes in this area include joint response, systemic activity, and cutaneous inflammation.

Sponsored Trials

Trial Name	Country	Status
A Phase 2b Randomized Study of IMVT-1402 Versus Placebo in Adult Patients with Graves' Disease	Bulgaria Czechia Germany Greece Italy Latvia Poland Spain The Netherlands	Recruiting
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Austria Belgium Bulgaria Denmark Estonia Finland Germany Greece Hungary Ireland Italy Norway Poland Portugal Romania Slovakia Slovenia Spain The Netherlands	Recruiting
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants with Primary Sjogren’s Disease with Moderate to Severe Systemic Disease Activity	Germany Greece Hungary Italy Poland Romania Spain	Recruiting
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis	Czechia Denmark Germany Greece Hungary Italy Poland Romania Spain	Recruiting
Efficacy and Safety Evaluation of IMVT-1402 in Adult Patients with Graves' Disease: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Trial	Belgium Germany Hungary Italy Poland Spain	Recruiting
Efficacy, Safety, and Tolerability of IMVT-1402 in ACPA-Positive Rheumatoid Arthritis: A Phase 2b Multicenter, Double-Blind, Placebo-Controlled Study	Bulgaria Czechia Germany Hungary Poland Romania Spain	Not Recruiting
Evaluation of Batoclimab Efficacy and Safety in an Open-Label Extension Study for Thyroid Eye Disease Treatment in Participants Completing IMVT-1401-3201/3202	Belgium Hungary Italy Latvia Poland Slovakia Spain	Not Recruiting
Evaluation of Batoclimab Efficacy and Safety in Patients with Graves' Disease: An Open-label, Proof-of-Concept Study	Germany	Not Recruiting
Evaluation of IMVT-1402 Efficacy and Safety in Active Subacute and Chronic Cutaneous Lupus Erythematosus: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Trial	Bulgaria Germany Greece Poland Spain	Not Recruiting
Long-Term Extension Study of Imeroprubart in Adult Patients With Graves' Disease	Belgium Bulgaria Czechia Germany Greece Hungary Italy Latvia Poland Spain The Netherlands	Recruiting